Differential prognosis of metastatic colorectal cancer patients post-progression to first-line triplet chemotherapy plus bevacizumab, FIr-B/FOx, according to second-line treatment and KRAS genotype

Clinical outcome post-progression to first-line triplet chemotherapy (CT) plus bevacizumab (FIr-B/FOx) was evaluated in metastatic colorectal cancer (MCRC) patients (pts). Second-line treatment was selected according to fitness, KRAS genotype, previous efficacy and safety. Efficacy was evaluated and...

Descripción completa

Detalles Bibliográficos
Autores principales: BRUERA, GEMMA, CANNITA, KATIA, GIORDANO, ALDO VICTOR, VICENTINI, ROBERTO, FICORELLA, CORRADO, RICEVUTO, ENRICO
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2013
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3867368/
https://www.ncbi.nlm.nih.gov/pubmed/24247407
http://dx.doi.org/10.3892/ijo.2013.2179

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3867368/
https://www.ncbi.nlm.nih.gov/pubmed/24247407
http://dx.doi.org/10.3892/ijo.2013.2179

Ejemplares similares